MICARDIA CORPORATION
MiCardia is a privately held medical device company currently preparing for the commercialization of its first series of products, enCor™, in the European Union. enCor is a unique device that surgically treats mitral valve regurgitation. enCor utilizes the company's patented technology, Dynaplasty™, to provide a "second chance" to the patient who develops recurrent regurgitation. enCor can be activated to physiologically adjust the mitral valve leaflets to resolve regurgitation, minimally invasively, weeks to years later, without the need for the risk and cost of redo surgery.
MICARDIA CORPORATION
Industry:
Health Care Medical Medical Device
Founded:
2004-01-01
Address:
Irvine, California, United States
Country:
United States
Website Url:
http://www.micardia.com
Total Employee:
11+
Status:
Active
Contact:
(949)951-4888
Email Addresses:
[email protected]
Total Funding:
28.93 M USD
Technology used in webpage:
SPF Amazon Google Maps Google Maps API Amazon Frankfurt Region
Similar Organizations
Conformal Medical
Conformal Medical is an early stage medical device company developing devices to prevent stroke in patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
DNX Ventures
DNX Ventures investment in Venture Round - MiCardia Corporation
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Venture Round - MiCardia Corporation
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - MiCardia Corporation
DNX Ventures
DNX Ventures investment in Series B - MiCardia Corporation
BioStar Capital
BioStar Capital investment in Series B - MiCardia Corporation
MedFocus Fund
MedFocus Fund investment in Series B - MiCardia Corporation
Official Site Inspections
http://www.micardia.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 13.248.169.48
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "MiCardia Corporation"
Home - ViCardia
Our mission: to be the leader in heart failure research and treatment focused on mitochondrial dysfunction and AMPK activation. Heart failure is the cardiovascular epidemic of the 21st …See details»
About Us - ViCardia
ViCardia Therapeutics, Inc., a Delaware corporation, founded in 2017, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for treating heart failure (HF) …See details»
ViCardia - Crunchbase Company Profile & Funding
ViCardia is ledmanagement team, board of directors and board of scientific advisors with extensive experience treating chronic and acute heart failure and conducting cardiovascular research. The company focused on the discovery, …See details»
Investors - ViCardia
Global market potential – HF is a worldwide public health crisis. From the perspective of the hospital, physician, care-giver and the payor, the reduced number of hospitalizations and re …See details»
ViCardia Therapeutics - Products, Competitors, Financials, …
ViCardia Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for heart failure, particularly targeting …See details»
Michael Kokesh - BIO Investor Forum | BIO
Mr. Kokesh is the founder of ViCardia Therapeutics, Inc. Prior work experience includes serving as the Chief Executive Officer of the Ischemia Research and Education Foundation, a leading …See details»
Home | VisCardia
VisCardia Inc., a privately held medical device developer in Portland Oregon, is developing a new implantable device therapy for heart failure.See details»
ViCardia Therapeutics, Inc. - VentureRadar
"ViCardia Therapeutics Inc., a privately held company founded in 2017, based in San Francisco, is entering Phase 2 with GP531, a potent, long-lasting infusion therapy that treats …See details»
ViCardia Therapeutics, Inc. | Life Sciences PA - Default Site
ViCardia Therapeutics, Inc., a Delaware corporation, founded in 2017, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of …See details»
ViCardia Therapeutics Inc. - BIO CEO & Investor …
ViCardia Therapeutics, headquartered in San Francisco, is developing GP-531, a novel treatment for heart failure, a condition affecting over 65 million people worldwide. GP-531 is a second-generation member of a novel class of …See details»
ViCardia Therapeutics, Inc. - BIO Investor Forum | BIO
ViCardia Therapeutics, a biopharmaceutical company, is entering Phase 2 with GP531, a potent, orally active therapy that treats mitochondrial dysfunction in heart failure. GP531 acts as an …See details»
GP-531 by ViCardia Therapeutics for Congestive Heart Failure …
Aug 28, 2024 · ViCardia Therapeutics (ViCardia) is a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes novel therapies to treat heart failures. The …See details»
ViCardia Therapeutics, Inc. - VentureRadar
ViCardia Therapeutics Inc., a privately held company founded in 2017, based in San Francisco, is entering Phase 2 with GP531, a potent, long-lasting infusion therapy that treats mitochondrial …See details»
CardiologyTrials.org - Improving evidence-based medicine
CardiologyTrials.org - Listing the most important trials in cardiologySee details»
Clinicians - ViCardia
ViCardia is entering Phase 2 with GP531, a potent, long-lasting, infusion therapy that treats mitochondrial dysfunction that leads to chronic heart failure and ultimately to acute …See details»
JoAnne M. Foody, MD | Cardiometabolic Health Congress
Dr. JoAnne M. Foody is a board-certified cardiologist and a respected leading clinical expert, particularly in the cardiovascular industry, with more than 30 years of experience.See details»
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF
Feb 28, 2022 · Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction …See details»
Accelerating Cardiac Care Diagnosis | Tricog Health
Our robust technology, medical-grade AI, and intuitive tools improve cardiac care of patient by solving cardiac care infrastructure, expertise, bandwidth, availability, and efficiency gaps.See details»
Patients - ViCardia
In our Phase 2 clinical trial, ViCardia intends to show that GP531 improves patient outcomes post-discharge. If successful, GP531 would provide the clear pathway to a life-saving therapy for …See details»
Vircadia | Open Source Metaverse Platform
Vircadia is a full coverage ecosystem of open source agent-based metaverse components that enables organizations to deploy their own virtual world solutions. With 4096km³ of space, …See details»